Emerging roles of the MiT/TFE factors in cancer.
| Autor: | Zoncu R; Department of Molecular and Cellular Biology, University of California at Berkeley, Berkeley, CA 94720, USA. Electronic address: rzoncu@berkeley.edu., Perera RM; Department of Anatomy, University of California San Francisco, San Francisco, CA 94143, USA; Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: rushika.perera@ucsf.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Trends in cancer [Trends Cancer] 2023 Oct; Vol. 9 (10), pp. 817-827. Date of Electronic Publication: 2023 Jul 01. |
| DOI: | 10.1016/j.trecan.2023.06.005 |
| Abstrakt: | The microphthalmia/transcription factor E (MiT/TFE) transcription factors (TFs; TFEB, TFE3, MITF, and TFEC) play a central role in cellular catabolism and quality control and are subject to extensive layers of regulation that influence their localization, stability, and activity. Recent studies have highlighted a broader role for these TFs in driving diverse stress-adaptation pathways, which manifest in a context- and tissue-dependent manner. Several human cancers upregulate the MiT/TFE factors to survive extreme fluctuations in nutrients, energy, and pharmacological challenges. Emerging data suggest that reduced activity of the MiT/TFE factors can also promote tumorigenesis. Here, we outline recent findings relating to novel mechanisms of regulation and activity of MiT/TFE proteins across some of the most aggressive human cancers. Competing Interests: Declaration of interests R.Z. is a co-founder, shareholder, and consultant for Frontier Medicines Corp. and a consultant for Nine Square Therapeutics. R.M.P. has no interests to declare. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|